These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 33362390)

  • 21. Crohn´s disease is an independent risk factor for liver fibrosis in patients with inflammatory bowel disease and non-alcoholic fatty liver disease.
    Martínez-Domínguez SJ; García-Mateo S; Gargallo-Puyuelo CJ; Gallego Llera B; Refaie E; Callau P; Mendi C; Baptista PM; Hernández Ainsa M; Arroyo-Villarino MT; López de la Cruz J; Martínez-García J; Alfambra E; Simón Marco MÁ; Ampuero J; Gomollón F
    Eur J Intern Med; 2024 Feb; 120():99-106. PubMed ID: 37872034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatic Steatosis but Not Fibrosis Is Independently Associated with Poor Outcomes in Patients with Inflammatory Bowel Disease.
    Hyun HK; Lee HW; Park J; Park SJ; Park JJ; Kim TI; Lee JS; Kim BK; Park JY; Kim DY; Ahn SH; Kim SU; Cheon JH
    Gut Liver; 2024 Mar; 18(2):294-304. PubMed ID: 37203442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NAFLD Is Associated With Quiescent Rather Than Active Crohn's Disease.
    McHenry S; Glover M; Ahmed A; Alayo Q; Zulfiqar M; Ludwig DR; Ciorba MA; Davidson NO; Deepak P
    Inflamm Bowel Dis; 2024 May; 30(5):757-767. PubMed ID: 37454277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article.
    Chao CY; Battat R; Al Khoury A; Restellini S; Sebastiani G; Bessissow T
    World J Gastroenterol; 2016 Sep; 22(34):7727-34. PubMed ID: 27678354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and predictors of non-alcoholic liver disease on MRI among patients with Crohn's disease.
    Hong Q; Shen J; Feng Q; Zheng Q; Qiao Y
    BMC Gastroenterol; 2022 Apr; 22(1):183. PubMed ID: 35413806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Derivation and Internal Validation of a Clinical Prediction Tool to Predict Nonalcoholic Fatty Liver Disease in Patients With Crohn's Disease.
    McHenry S; Tirath A; Tsai R; Sharma Y; Flores AG; Davidson NO; Fowler KJ; Ciorba MA; Deepak P
    Inflamm Bowel Dis; 2020 Nov; 26(12):1917-1925. PubMed ID: 31907542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Nonalcoholic Fatty Liver Disease With Lower Brain Volume in Healthy Middle-aged Adults in the Framingham Study.
    Weinstein G; Zelber-Sagi S; Preis SR; Beiser AS; DeCarli C; Speliotes EK; Satizabal CL; Vasan RS; Seshadri S
    JAMA Neurol; 2018 Jan; 75(1):97-104. PubMed ID: 29159396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of Nonalcoholic Fatty Liver Disease in Pediatric Patients With Inflammatory Bowel Disease.
    Cohen ME; Deepak P; Khanna G; Samson CM
    J Pediatr Gastroenterol Nutr; 2021 Apr; 72(4):574-578. PubMed ID: 33346578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inflammatory Bowel Diseases and Non-Alcoholic Fatty Liver Disease: Piecing a Complex Puzzle Together.
    Maresca R; Mignini I; Varca S; Calvez V; Termite F; Esposto G; Laterza L; Scaldaferri F; Ainora ME; Gasbarrini A; Zocco MA
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease Among Patients with Inflammatory Bowel Disease.
    Glassner K; Malaty HM; Abraham BP
    Inflamm Bowel Dis; 2017 Jun; 23(6):998-1003. PubMed ID: 28511199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liver Fibrosis in Non-Alcoholic Fatty Liver Disease and Progression to Hepatocellular Carcinoma in Patients with Inflammatory Bowel Disease: A Systematic Review.
    Martínez-Domínguez SJ; García-Mateo S; Laredo V; Gargallo-Puyuelo CJ; Gallego Llera B; López de la Cruz J; Gomollón F
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between nonalcoholic fatty liver disease and incidence of inflammatory bowel disease: a nationwide population‑based cohort study.
    Wang YH; Chung CH; Huang TY; Chang CF; Yang CW; Chien WC; Cheng YC
    Intest Res; 2024 Feb; ():. PubMed ID: 38373704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
    Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B
    Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of nonalcoholic fatty liver disease and liver cancer.
    Schulz PO; Ferreira FG; Nascimento Mde F; Vieira A; Ribeiro MA; David AI; Szutan LA
    World J Gastroenterol; 2015 Jan; 21(3):913-8. PubMed ID: 25624725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic dysfunction-associated steatotic liver disease prevalence and risk factors in inflammatory bowel disease in tertiary center.
    Oliveira LDRP; Ribeiro TCDR; Mourao Junior CA; Barra MAL; Silva MHG; Shafee LP; Zacarias SM; Campos LDC; Valério HMG; Chebli JMF
    Rev Assoc Med Bras (1992); 2024; 70(6):e20231321. PubMed ID: 39045949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Significance of non-alcoholic fatty liver disease in Crohn's disease: A retrospective cohort study.
    Sagami S; Ueno Y; Tanaka S; Fujita A; Hayashi R; Oka S; Hyogo H; Chayama K
    Hepatol Res; 2017 Aug; 47(9):872-881. PubMed ID: 27737498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. P045 Prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with inflammatory bowel disease (IBD) in a Brazilian public healthcare clinic.
    Lopes M; Shintaku D; de Oliveira AC; Beraldo R; Godoi G; Castelhano N; Vulcano D; Pereira J; de Oliveira EC; Herrerias G; Saad-Hossne R; Baima J; Barbosa W; Silva G; Sassaki L
    Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S11-S12. PubMed ID: 37461963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multifaceted pathogenesis of liver steatosis in inflammatory bowel disease: a systematic review.
    Spagnuolo R; Abenavoli L; Corea A; Larussa T; Mancina RM; Cosco C; Luzza F; Doldo P
    Eur Rev Med Pharmacol Sci; 2021 Sep; 25(18):5818-5825. PubMed ID: 34604973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-alcoholic fatty liver disease and its associations among adolescents in an urban, Sri Lankan community.
    Rajindrajith S; Pathmeswaran A; Jayasinghe C; Kottahachchi D; Kasturiratne A; de Silva ST; Niriella MA; Dassanayake AS; de Silva AP; de Silva HJ
    BMC Gastroenterol; 2017 Nov; 17(1):135. PubMed ID: 29187144
    [TBL] [Abstract][Full Text] [Related]  

  • 40.  Most overweight and obese Indian children have nonalcoholic fatty liver disease.
    Pawar SV; Zanwar VG; Choksey AS; Mohite AR; Jain SS; Surude RG; Contractor QQ; Rathi PM; Verma RU; Varthakavi PK
    Ann Hepatol; 2016 Nov-Dec 2016; 15(6):853-861. PubMed ID: 27740518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.